Provided by Tiger Fintech (Singapore) Pte. Ltd.

Qudian Inc.

2.97
-0.0200-0.67%
Post-market: 2.970.00000.00%16:04 EDT
Volume:135.77K
Turnover:402.38K
Market Cap:490.43M
PE:12.02
High:3.00
Open:2.98
Low:2.94
Close:2.99
Loading ...

Third Harmonic Bio Announces Phase 1 Clinical Results for THB335 and Provides Corporate Strategic Update

GlobeNewswire
·
11 Feb

Arcus Biosciences to Present New Data from Casdatifan, a HIF-2a Inhibitor, in an Oral Presentation at the 2025 ASCO GU Symposium

Business Wire
·
11 Feb

Pfizer Reports Strong Full-Year 2024 Results And Reaffirms 2025 Guidance

Business Wire
·
04 Feb

Stock Track | Qudian Inc. Plummets 5.05% as Auditor Change Raises Concerns Over Financial Reporting

Stock Track
·
01 Feb

Qudian Inc. Announces Appointment of Auditor

THOMSON REUTERS
·
31 Jan

Qudian Inc. Announces Appointment of Auditor

PR Newswire
·
31 Jan

3 Promising Penny Stocks On US Exchanges In January 2025

Simply Wall St.
·
21 Jan

C4 Therapeutics Announces 2025 Milestones Across Clinical Portfolio of Degrader Medicines Pursuing Targets of High Unmet Need in Oncology

GlobeNewswire
·
14 Jan

Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Non-Muscle Invasive Bladder Cancer (SURF302)

PR Newswire
·
10 Jan

Samsung Display to Unveil QD-OLED Panels at CES 2025

MT Newswires Live
·
07 Jan

MicroCloud Hologram Inc. Develops Semiconductor Quantum Dot Hole Spin Qubit Technology, Advancing the Frontiers of Quantum Computing

PR Newswire
·
30 Dec 2024

Asian Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading

MT Newswires Live
·
23 Dec 2024

Aadi Bioscience Leads 3 Promising US Penny Stocks

Simply Wall St.
·
23 Dec 2024

InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904

GlobeNewswire
·
20 Dec 2024

Rigel Highlights Initial Data from Ongoing Phase 1b Study Evaluating R289 in LR-MDS at the 66th ASH Annual Meeting and Exposition

PR Newswire
·
10 Dec 2024

Enanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV)

Business Wire
·
09 Dec 2024